Cargando…

[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case

Detalles Bibliográficos
Autores principales:	Smith, Ruben, Pawlik, Daria, Nilsson, Christer F., Englund, Elisabet, Hansson, Oskar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989415/ https://www.ncbi.nlm.nih.gov/pubmed/31903496 http://dx.doi.org/10.1007/s00401-019-02121-w

Ejemplares similares

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

Validation of the new pathology staging system for progressive supranuclear palsy
por: Briggs, Mayen, et al.
Publicado: (2021)

In Vivo (18)F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy
por: Malpetti, Maura, et al.
Publicado: (2022)

Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants
por: Whitwell, Jennifer L., et al.
Publicado: (2019)

Increased basal ganglia binding of (18) F‐AV‐1451 in patients with progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

Selective tau seeding assays and isoform-specific antibodies define neuroanatomic distribution of progressive supranuclear palsy pathology arising in Alzheimer’s disease
por: Coughlin, David G., et al.
Publicado: (2022)

Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy
por: Surova, Yulia, et al.
Publicado: (2015)

Distribution patterns of tau pathology in progressive supranuclear palsy
por: Kovacs, Gabor G., et al.
Publicado: (2020)

Neuroimaging-pathological correlations of [(18)F]THK5351 PET in progressive supranuclear palsy
por: Ishiki, Aiko, et al.
Publicado: (2018)

Head-to-head comparison of tau positron emission tomography tracers [(18)F]flortaucipir and [(18)F]RO948
por: Smith, Ruben, et al.
Publicado: (2019)

Accurate digital quantification of tau pathology in progressive supranuclear palsy
por: Pansuwan, Tanrada, et al.
Publicado: (2023)

Florid Nonmotor Manifestations of a Pathologically proven Progressive Supranuclear Palsy
por: Shin, Chaewon, et al.
Publicado: (2018)

The genetic and clinico‐pathological profile of early‐onset progressive supranuclear palsy
por: Jabbari, Edwin, et al.
Publicado: (2019)

Assessment of Tau Pathology as Measured by (18)F-THK5317 and (18)F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer’s Disease
por: Colato, Elisa, et al.
Publicado: (2021)

Pathological Study of a FMR1 Premutation Carrier With Progressive Supranuclear Palsy
por: Paucar, Martin, et al.
Publicado: (2018)

Erratum: Florid Nonmotor Manifestations of a Pathologically proven Progressive Supranuclear Palsy
Publicado: (2019)

Locus coeruleus pathology in progressive supranuclear palsy, and its relation to disease severity
por: Kaalund, Sanne Simone, et al.
Publicado: (2020)

(18)F-Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy
por: Liu, Feng-Tao, et al.
Publicado: (2023)

(18)F-Flortaucipir in TDP-43 associated frontotemporal dementia
por: Smith, R., et al.
Publicado: (2019)

Contribution of the astrocytic tau pathology to synapse loss in progressive supranuclear palsy and corticobasal degeneration
por: Briel, Nils, et al.
Publicado: (2020)

Unsupervised [(18)F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer’s disease
por: Quattrini, Giulia, et al.
Publicado: (2023)

Microtubule defects in mesenchymal stromal cells distinguish patients with Progressive Supranuclear Palsy
por: Calogero, Alessandra Maria, et al.
Publicado: (2018)

Parametric methods for [(18)F]flortaucipir PET
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Pathological tau signatures and nuclear alterations in neurons, astrocytes and microglia in Alzheimer's disease, progressive supranuclear palsy, and dementia with Lewy bodies
por: Montalbano, Mauro, et al.
Publicado: (2022)

(18)F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy
por: Passamonti, Luca, et al.
Publicado: (2017)

Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism
por: Sjöström, Henrik, et al.
Publicado: (2019)

MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous
por: Josephs, Keith A., et al.
Publicado: (2020)

Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study
por: Pontecorvo, Michael J., et al.
Publicado: (2020)

A Case of Pathologically Confirmed Corticobasal Degeneration Initially Presenting as Progressive Supranuclear Palsy Syndrome
por: Chung, Eun Joo, et al.
Publicado: (2022)

Association of the top 20 Alzheimer's disease risk genes with [(18)F]flortaucipir PET
por: Stage, Eddie, et al.
Publicado: (2022)

Tau pathology in aged cynomolgus monkeys is progressive supranuclear palsy/corticobasal degeneration- but not Alzheimer disease-like -Ultrastructural mapping of tau by EDX-
por: Uchihara, Toshiki, et al.
Publicado: (2016)

Image-level trajectory inference of tau pathology using variational autoencoder for Flortaucipir PET
por: Hong, Jimin, et al.
Publicado: (2022)

Hippocampal [(18)F]flortaucipir BP(ND) corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships
por: Wolters, Emma E, et al.
Publicado: (2019)

Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease
por: Spotorno, Nicola, et al.
Publicado: (2022)

Unusual phenotype of pathologically confirmed progressive supranuclear palsy with autonomic dysfunction and cerebellar ataxia: Case report
por: Mensikova, Katerina, et al.
Publicado: (2016)

Co-morbidity of progressive supranuclear palsy and amyotrophic lateral sclerosis: a clinical-pathological case report
por: Fujita, Koji, et al.
Publicado: (2019)

Actin-binding protein filamin-A drives tau aggregation and contributes to progressive supranuclear palsy pathology
por: Tsujikawa, Koyo, et al.
Publicado: (2022)

Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive Supranuclear Palsy Tau Pathology With [(18)F]PI-2620
por: Willroider, Marie, et al.
Publicado: (2021)

Test–retest repeatability of [(18)F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals
por: Timmers, Tessa, et al.
Publicado: (2019)

International consensus on the use of tau PET imaging agent (18)F-flortaucipir in Alzheimer’s disease
por: Tian, Mei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_00imcpkdpg693re8r4s9ob8qe7